CA2523178C - Materials and methods to potentiate cancer treatment - Google Patents
Materials and methods to potentiate cancer treatment Download PDFInfo
- Publication number
- CA2523178C CA2523178C CA2523178A CA2523178A CA2523178C CA 2523178 C CA2523178 C CA 2523178C CA 2523178 A CA2523178 A CA 2523178A CA 2523178 A CA2523178 A CA 2523178A CA 2523178 C CA2523178 C CA 2523178C
- Authority
- CA
- Canada
- Prior art keywords
- dna
- compound
- test compound
- group
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/16—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with acyl radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
- C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
- C07D311/86—Oxygen atoms, e.g. xanthones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45699903P | 2003-03-24 | 2003-03-24 | |
| US60/456,999 | 2003-03-24 | ||
| PCT/US2004/008459 WO2004085418A2 (en) | 2003-03-24 | 2004-03-19 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2523178A1 CA2523178A1 (en) | 2004-10-07 |
| CA2523178C true CA2523178C (en) | 2012-10-23 |
Family
ID=33098184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2523178A Expired - Fee Related CA2523178C (en) | 2003-03-24 | 2004-03-19 | Materials and methods to potentiate cancer treatment |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8404681B2 (enExample) |
| EP (1) | EP1660473A2 (enExample) |
| JP (1) | JP2006523681A (enExample) |
| AU (1) | AU2004223866A1 (enExample) |
| CA (1) | CA2523178C (enExample) |
| WO (1) | WO2004085418A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE502928T1 (de) | 2000-11-01 | 2011-04-15 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| AU2005222607B2 (en) | 2004-03-15 | 2010-11-25 | Sunesis Pharmaceuticals, Inc. | SNS-595 and methods of using the same |
| US8936809B2 (en) * | 2005-03-31 | 2015-01-20 | Lidds Ab | Method for treating prostate diseases based on local delivery of active substances |
| US8580814B2 (en) | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| US8124773B2 (en) | 2006-06-12 | 2012-02-28 | Sunesis Pharmaceuticals, Inc. | 1,8-naphthyridine compounds for the treatment of cancer |
| MX2010004350A (es) | 2007-10-22 | 2010-05-19 | Sunesis Pharmaceuticals Inc | Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion. |
| LT2280720T (lt) | 2008-03-27 | 2019-07-25 | Purdue Research Foundation | Kolageną surišantys sintetiniai peptidoglikanai, jų paruošimas ir naudojimo būdai |
| ES2742218T3 (es) * | 2010-06-23 | 2020-02-13 | Purdue Research Foundation | Peptidoglicanos sintéticos que se enlazan al colágeno destinados a ser utilizados en operaciones vasculares |
| TWI414520B (zh) * | 2010-10-06 | 2013-11-11 | Nat Defense Medical Ct | 噻噸酮衍生物 |
| US8618125B2 (en) | 2011-01-14 | 2013-12-31 | Heptiva LLC | Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance |
| PT2714718T (pt) | 2011-05-24 | 2017-04-19 | Symic Ip Llc | Preparação e métodos de utilização de peptidoglicanas sintéticas que se ligam a ácido hialurónico |
| LT2841428T (lt) | 2012-04-24 | 2018-12-10 | Vertex Pharmaceuticals Incorporated | Dnr-pk inhibitoriai |
| CN105246883B (zh) | 2013-03-12 | 2017-07-21 | 沃泰克斯药物股份有限公司 | Dna‑pk抑制剂 |
| US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| EP2970509B1 (en) | 2013-03-15 | 2020-05-13 | Purdue Research Foundation | Extracellular matrix-binding synthetic peptidoglycans |
| ES2714708T3 (es) | 2013-10-01 | 2019-05-29 | Mayo Found Medical Education & Res | Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
| WO2015164822A1 (en) | 2014-04-25 | 2015-10-29 | Purdue Research Foundation | Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction |
| US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
| EP3171896A4 (en) | 2014-07-23 | 2018-03-21 | Mayo Foundation for Medical Education and Research | Targeting dna-pkcs and b7-h1 to treat cancer |
| CN104610276B (zh) * | 2014-11-06 | 2016-08-17 | 浙江工业大学 | 苯并[k,l]噻吨-3,4-二甲酸酐类衍生物-尿苷偶联物及其制备方法和应用 |
| JP2018507227A (ja) | 2015-03-03 | 2018-03-15 | キュアポート インコーポレイテッド | 二薬搭載リポソーム医薬製剤 |
| EP3265059A4 (en) | 2015-03-03 | 2018-08-29 | Cureport Inc. | Combination liposomal pharmaceutical formulations |
| WO2016174674A1 (en) * | 2015-04-27 | 2016-11-03 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions |
| US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
| JP6957522B2 (ja) | 2016-05-26 | 2021-11-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス疾患の治療および予防のためのキサントン誘導体 |
| TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
| US20200101080A1 (en) * | 2017-03-31 | 2020-04-02 | Bioventures, Llc | Inhibitors of dna pk and uses thereof |
| JP2020526497A (ja) | 2017-07-07 | 2020-08-31 | サイミック アイピー， エルエルシー | 合成バイオコンジュゲート |
| EP3740483B1 (en) | 2018-01-17 | 2023-01-11 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
| JP7466448B2 (ja) | 2018-01-17 | 2024-04-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｄｎａ－ｐｋ阻害剤 |
| MA51619A (fr) * | 2018-01-17 | 2021-04-14 | Vertex Pharma | Inhibiteurs de la protéine kinase dépendante de l'adn |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN109369599B (zh) * | 2018-11-15 | 2023-03-24 | 广州医科大学 | 一种呫吨酮类化合物及其制备方法和应用 |
| WO2020180845A1 (en) * | 2019-03-04 | 2020-09-10 | University Of Washington | Methods for treating autoimmune or autoinflammatory disease |
| CN118388410B (zh) * | 2024-04-23 | 2025-07-18 | 仁合益康集团有限公司 | 一种吗啉硝唑的合成方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE630639A (enExample) | 1962-04-12 | |||
| FR8298M (enExample) | 1967-07-20 | 1970-11-16 | ||
| US3835158A (en) * | 1972-05-17 | 1974-09-10 | Syntex Inc | Heterocyclic substituted xanthone carboxylic acid compounds |
| JPS5138245B2 (enExample) * | 1973-05-22 | 1976-10-20 | ||
| US3904631A (en) * | 1973-05-29 | 1975-09-09 | Parke Davis & Co | Novel thioxanthenone compounds and means of producing the same |
| US4003699A (en) * | 1974-11-22 | 1977-01-18 | Henkel & Cie G.M.B.H. | Oxidation hair dyes based upon tetraaminopyrimidine developers |
| DE2807761A1 (de) * | 1978-02-23 | 1979-08-30 | Basf Ag | Cumarinderivate |
| DE2922488A1 (de) | 1979-06-01 | 1980-12-11 | Thiemann Chem Pharm Fab | 2-hydroxy-4-methyl-benzolverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| JPS578845A (en) | 1980-06-18 | 1982-01-18 | Fujitsu Ltd | Indeterminate processing control system |
| DE3141970A1 (de) | 1981-10-22 | 1983-05-05 | Vsesojuznyj naučno-issledovatel'skij institut lekarstvennych rastenij, Vilar, Moskovskaja oblast' | Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen |
| US4436732A (en) * | 1981-10-26 | 1984-03-13 | Vichkanova Serafima A | Medicated compound for treating diseases infected by virus of the herpes group |
| EP0082109A3 (de) | 1981-10-28 | 1985-04-17 | Ciba-Geigy Ag | Substituierte 2-Hydroxy-phenylessigsäuren und Derivate davon |
| US4426380A (en) * | 1981-10-28 | 1984-01-17 | Ciba-Geigy Corporation | Benzofuran-2-ones and pharmaceutical compositions |
| US4539412A (en) * | 1982-07-08 | 1985-09-03 | Rensselaer Polytechnic Institute | 7-Hydroxylucanthone, 7-hydroxhycanthone and their analogs |
| IL69898A0 (en) * | 1982-10-08 | 1984-01-31 | Ciba Geigy Ag | Furans |
| EP0107620A1 (de) | 1982-10-13 | 1984-05-02 | Ciba-Geigy Ag | Phenol-Derivate |
| DE3800577A1 (de) * | 1988-01-12 | 1989-07-20 | Basf Ag | 3-(4-amino-2-hydroxyphenyl)-1-oxo-isoindolenine, verfahren zu deren herstellung und deren verseifung zu 2-(4-amino-2-hydroxybenzoyl)-benzoesaeuren |
| US4935543A (en) | 1988-05-20 | 1990-06-19 | Takeda Chemical Industries, Ltd. | Physiologically active substance tan-931, its derivatives, their production and use |
| AU5831090A (en) | 1989-05-25 | 1990-12-18 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for inhibiting tumor cell growth |
| GB9018044D0 (en) | 1990-08-16 | 1990-10-03 | Ici Plc | Tricyclic heterocyclic derivatives |
| JPH06506202A (ja) | 1991-03-22 | 1994-07-14 | ゼノバ リミテッド | 医薬用キサントン誘導体 |
| DE69223422T2 (de) * | 1991-05-24 | 1998-04-09 | Taiho Pharmaceutical Co. Ltd., Tokio/Tokyo | Benzothiadiazinderivate |
| US5262549A (en) * | 1991-05-30 | 1993-11-16 | Polaroid Corporation | Benzpyrylium dyes, and processes for their preparation and use |
| JPH04368379A (ja) | 1991-06-13 | 1992-12-21 | Natl Sci Council | キサントン誘導体又はそのエステルを有効成分とする血栓予防治療剤 |
| WO1995020652A1 (de) | 1994-01-28 | 1995-08-03 | Medigene Gmbh | Verfahren zur bestimmung der aktivität eines regulatorischen faktors sowie verwendung dieses verfahrens |
| DE4424712A1 (de) | 1994-07-13 | 1996-01-18 | Basf Ag | Verwendung von Benzaldehyden zum Markieren von Kohlenwasserstoffen |
| CA2180745A1 (fr) * | 1994-11-25 | 1996-06-06 | Francoise Rouillard | Compositions cosmetiques ou pharmaceutiques contenant de la mangiferine ou ses derives |
| DE19501303A1 (de) | 1995-01-18 | 1996-07-25 | Henkel Kgaa | Arylketone zum Färben keratinhaltiger Fasern |
| USRE39088E1 (en) * | 1995-08-22 | 2006-05-02 | Japan Tobacco, Inc. | Amide compounds and use of the same |
| WO1997031891A1 (en) | 1996-03-01 | 1997-09-04 | Merck & Co., Inc. | Process for regioselective substitution of trifluorobenzoate or trifluorobenzonitrile |
| JPH09316440A (ja) | 1996-05-27 | 1997-12-09 | Toyo Ink Mfg Co Ltd | 有機エレクトロルミネッセンス素子材料およびそれを用いた有機エレクトロルミネッセンス素子 |
| WO1998013502A2 (en) | 1996-09-27 | 1998-04-02 | Icos Corporation | Method to identify compounds for disrupting protein/protein interactions |
| GB2326410A (en) | 1997-06-18 | 1998-12-23 | Merck & Co Inc | Tocolytic Oxytocin Receptor Antagonists |
| JPH11106371A (ja) | 1997-07-04 | 1999-04-20 | Nisshin Flour Milling Co Ltd | アシルヒドラゾン誘導体 |
| SE9703377D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
| JP4531149B2 (ja) | 1997-10-17 | 2010-08-25 | 富山化学工業株式会社 | 含窒素三・四環式化合物およびそれを含有する抗ウイルス剤 |
| AU1804299A (en) | 1997-12-08 | 1999-06-28 | Glycomed Incorporated | Sialyl lewis x and sialyl lewis a glycomimetics |
| CN1295680A (zh) | 1998-01-30 | 2001-05-16 | 第一化学公司 | 含有马来酰亚胺的光致聚合组合物及其使用方法 |
| WO2000000644A1 (en) | 1998-06-30 | 2000-01-06 | Sloan-Kettering Institute For Cancer Research | Uses of dna-pk |
| AU6055099A (en) | 1998-09-21 | 2000-04-10 | Fox Chase Cancer Center | Assays and novel cellular targets for therapeutic agents to treat retroviral infection |
| SK4172001A3 (en) | 1998-09-28 | 2001-11-06 | Kimberly Clark Co | Chelates comprising chinoid groups as photoinitiators |
| GB9920912D0 (en) | 1999-09-03 | 1999-11-10 | Indena Spa | Novel derivatives of flavones,xanthones and coumarins |
| US6535593B1 (en) * | 2000-02-28 | 2003-03-18 | Simplified Development Corp. | System and method for billing communications services provisioned on demand in converging telecommunications network |
| JP2001247459A (ja) * | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
| US7179912B2 (en) * | 2000-09-01 | 2007-02-20 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| WO2003055479A1 (en) | 2001-12-21 | 2003-07-10 | Consejo Superior De Investigaciones Cientificas | Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3 |
-
2004
- 2004-03-19 CA CA2523178A patent/CA2523178C/en not_active Expired - Fee Related
- 2004-03-19 US US10/550,978 patent/US8404681B2/en not_active Expired - Fee Related
- 2004-03-19 WO PCT/US2004/008459 patent/WO2004085418A2/en not_active Ceased
- 2004-03-19 JP JP2006507373A patent/JP2006523681A/ja active Pending
- 2004-03-19 EP EP04757891A patent/EP1660473A2/en not_active Withdrawn
- 2004-03-19 AU AU2004223866A patent/AU2004223866A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004085418A3 (en) | 2005-01-27 |
| US8404681B2 (en) | 2013-03-26 |
| US20070167441A1 (en) | 2007-07-19 |
| CA2523178A1 (en) | 2004-10-07 |
| WO2004085418A2 (en) | 2004-10-07 |
| AU2004223866A1 (en) | 2004-10-07 |
| JP2006523681A (ja) | 2006-10-19 |
| EP1660473A2 (en) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2523178C (en) | Materials and methods to potentiate cancer treatment | |
| US7179912B2 (en) | Materials and methods to potentiate cancer treatment | |
| JP6395893B2 (ja) | 癌ならびに免疫疾患および自己免疫疾患の治療のためのアポトーシス誘発剤としての８−カルバモイル−２−（２，３−ジ置換ピリド−６−イル）−１，２，３，４−テトラヒドロイソキノリン誘導体 | |
| CN103052627B (zh) | 作为fak抑制剂的嘧啶衍生物 | |
| CA2850976C (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| CN105164136B (zh) | 作为激酶抑制剂的大环化合物 | |
| US20090118503A1 (en) | Faah inhibitors | |
| BRPI0813707B1 (pt) | Derivados de pirimidinil-piridazinona, seu uso, e medicamentos | |
| JP6692759B2 (ja) | 新規キノリン誘導体及び神経変性疾患におけるそれらの使用 | |
| US7385061B2 (en) | Furazanobenzimidazoles | |
| IL233984A (en) | The history of tetrahydro-quinazolinone, their preparation and their pharmaceutical preparations | |
| MX2007000265A (es) | Compuestos utiles para inhibir chk1. | |
| EA019322B1 (ru) | Производные пиридазинона | |
| JP5227179B2 (ja) | ３，６−ジヒドロ−２−オキソ−６ｈ−１，３，４−チアジアジン誘導体 | |
| TWI764201B (zh) | 可用為幾丁質酶抑制劑的經取代的胺基三唑 | |
| EA021067B1 (ru) | Производные бензотиазолона | |
| RU2663623C2 (ru) | Фталазиновые производные | |
| AU2005267185A1 (en) | Bisarylurea derivatives useful for inhibiting CHK1 | |
| EA020574B1 (ru) | Производные пиридазинона для применения в лечении заболеваний, индуцированных киназой | |
| CN105246899A (zh) | 作为抗癌药物的gem-二氟化c-糖苷化合物 | |
| CN113166097A (zh) | 作为端锚聚合酶抑制剂的4-杂芳基羰基-n-(苯基或杂芳基)哌啶-1-甲酰胺 | |
| HK1202551B (en) | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors | |
| HK1125930A (en) | 3,6-dihydro-2-oxo-6h-(1,3,4)-thiadiazine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170320 |